miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
22 10 2020
Historique:
received: 05 12 2019
accepted: 24 08 2020
revised: 13 08 2020
entrez: 23 10 2020
pubmed: 24 10 2020
medline: 10 4 2021
Statut: epublish

Résumé

Glioblastoma (GBM) is a highly aggressive tumor with poor prognosis. A small subpopulation of glioma stem cells (GSCs) has been implicated in radiation resistance and tumor recurrence. In this study we analyzed the expression of miRNAs associated with the functions of GSCs using miRNA microarray analysis of these cells compared with human neural stem cells. These analyses identified gene clusters associated with glioma cell invasiveness, axonal guidance, and TGF-β signaling. miR-504 was significantly downregulated in GSCs compared with NSCs, its expression was lower in GBM compared with normal brain specimens and further decreased in the mesenchymal glioma subtype. Overexpression of miR-504 in GSCs inhibited their self-renewal, migration and the expression of mesenchymal markers. The inhibitory effect of miR-504 was mediated by targeting Grb10 expression which acts as an oncogene in GSCs and GBM. Overexpression of exogenous miR-504 resulted also in its delivery to cocultured microglia by GSC-secreted extracellular vesicles (EVs) and in the abrogation of the GSC-induced polarization of microglia to M2 subtype. Finally, miR-504 overexpression prolonged the survival of mice harboring GSC-derived xenografts and decreased tumor growth. In summary, we identified miRNAs and potential target networks that play a role in the stemness and mesenchymal transition of GSCs and the miR-504/Grb10 pathway as an important regulator of this process. Overexpression of miR-504 exerted antitumor effects in GSCs as well as bystander effects on the polarization of microglia via delivery by EVs.

Identifiants

pubmed: 33093452
doi: 10.1038/s41419-020-03088-3
pii: 10.1038/s41419-020-03088-3
pmc: PMC7581800
doi:

Substances chimiques

GRB10 protein, human 0
MIRN504 microRNA, human 0
MicroRNAs 0
GRB10 Adaptor Protein 151441-47-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

899

Références

PLoS One. 2017 Jan 5;12(1):e0168412
pubmed: 28056026
J BUON. 2017 Mar-Apr;22(2):474-480
pubmed: 28534372
Semin Cell Dev Biol. 2015 Apr;40:17-26
pubmed: 25721810
Neuro Oncol. 2012 Sep;14(9):1153-62
pubmed: 22844109
Int J Clin Exp Pathol. 2015 Jan 01;8(1):727-34
pubmed: 25755767
Mol Cancer Res. 2006 Sep;4(9):607-19
pubmed: 16966431
J Exp Clin Cancer Res. 2019 Aug 16;38(1):358
pubmed: 31419987
Oncotarget. 2014 Jul 30;5(14):5663-73
pubmed: 25015107
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5248-53
pubmed: 24706837
Cell Death Dis. 2018 Dec 11;9(12):1190
pubmed: 30538217
ACS Med Chem Lett. 2015 Jun 22;6(8):948-52
pubmed: 26288699
Cell Mol Neurobiol. 2016 Apr;36(3):361-76
pubmed: 26983830
Int J Cancer. 2015 Oct 1;137(7):1630-42
pubmed: 25802036
Neuro Oncol. 2007 Oct;9(4):424-9
pubmed: 17622647
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Front Oncol. 2019 Aug 20;9:779
pubmed: 31482066
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Neuro Oncol. 2016 Jan;18(1):58-69
pubmed: 26433199
Brain. 2019 Apr 1;142(4):847-866
pubmed: 30946477
Oncotarget. 2013 Feb;4(2):346-61
pubmed: 23548312
Int J Mol Sci. 2019 Jun 04;20(11):
pubmed: 31167470
Cancer Lett. 2016 Apr 28;374(1):1-11
pubmed: 26854715
Am J Cancer Res. 2015 Feb 15;5(3):945-55
pubmed: 26045979
Nature. 2010 Jan 21;463(7279):318-25
pubmed: 20032975
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Arterioscler Thromb Vasc Biol. 2016 May;36(5):864-73
pubmed: 26941017
Cancers (Basel). 2018 Dec 22;11(1):
pubmed: 30583549
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Front Immunol. 2018 May 08;9:1004
pubmed: 29867979
PLoS Genet. 2015 May 22;11(5):e1005235
pubmed: 26000738
Cancer Lett. 2018 Feb 1;414:107-115
pubmed: 29107112
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
FASEB J. 2019 Mar;33(3):3198-3211
pubmed: 30379590
Oncotarget. 2013 May;4(5):665-76
pubmed: 23714687
Oncotarget. 2015 Aug 14;6(23):19826-40
pubmed: 26305187
Cancer Lett. 2017 Apr 1;390:176-187
pubmed: 28007636
Oncotarget. 2016 Aug 30;7(35):56456-56470
pubmed: 27486821
Genes Dev. 2007 Nov 1;21(21):2683-710
pubmed: 17974913
Int J Cancer. 2014 Sep 1;135(5):1019-27
pubmed: 24500893
Mol Neurobiol. 2013 Feb;47(1):131-44
pubmed: 23054677
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
PLoS One. 2013;8(2):e54652
pubmed: 23390502
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Stem Cells Dev. 2014 Dec 1;23(23):2851-61
pubmed: 25036385
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Nat Rev Cancer. 2006 Jun;6(6):425-36
pubmed: 16723989
Oncotarget. 2015 Sep 8;6(26):22680-97
pubmed: 26267319
Front Biosci. 2005 Sep 01;10:2645-68
pubmed: 15970525
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Cancer Lett. 2016 Feb 28;371(2):301-13
pubmed: 26683775
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):6841-7
pubmed: 25368187
Cancer Res. 2011 Sep 15;71(18):5950-4
pubmed: 21917736
Cell Rep. 2019 Sep 17;28(12):3105-3119.e7
pubmed: 31533034
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Oncogene. 2012 May 10;31(19):2401-11
pubmed: 21927029
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Neuro Oncol. 2012 Aug;14(8):958-78
pubmed: 22573310
Med Res Rev. 2017 Mar;37(2):271-313
pubmed: 27617697
Cell. 2010 Jun 25;141(7):1195-207
pubmed: 20603000
Biomaterials. 2018 Aug;174:67-78
pubmed: 29783118
Neuro Oncol. 2015 May;17(5):652-62
pubmed: 25301812
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046

Auteurs

Ariel Bier (A)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Xin Hong (X)

Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.

Simona Cazacu (S)

Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.

Hodaya Goldstein (H)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Daniel Rand (D)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Cunli Xiang (C)

Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.

Wei Jiang (W)

Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.

Hiba Waldman Ben-Asher (HW)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Moshe Attia (M)

Department of Neurosurgery, Sheba Medical Center, Henry Ford Hospital, Detroit, MI, USA.

Aharon Brodie (A)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Ruicong She (R)

Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.

Laila M Poisson (LM)

Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.

Chaya Brodie (C)

The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel. chaya@brodienet.com.
Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA. chaya@brodienet.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH